



**October 8, 2026**

**Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc.**

Novo Nordisk Inc. has recalculated its 340B ceiling prices for the period of 2Q 2026 for the products listed below due to revisions made to its Medicaid pricing data. Novo Nordisk Inc. has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about Novo Nordisk Inc.'s recalculation affecting certain 340B Covered Entities for the impacted products.

Novo Nordisk Inc. has determined the credit amount owed to each affected Covered Entity. Novo Nordisk Inc. will be coordinating with its wholesalers to issue refunds to each affected Covered Entity. Refunds will be issued to a Covered Entity's validated wholesaler pharmacy account when one can be identified.

| NDC           | Product Description       | Period |
|---------------|---------------------------|--------|
| 00169-4404-31 | WEGOVY 4MG BOTTLE         | 2Q2026 |
| 00169-4409-31 | WEGOVY 9MG BOTTLE         | 2Q2026 |
| 00169-4415-31 | WEGOVY 1.5MG BOTTLE       | 2Q2026 |
| 00169-4425-31 | WEGOVY 25MG BOTTLE        | 2Q2026 |
| 00169-4572-14 | WEGOVY 7.2 MG 4 PREF PENS | 2Q2026 |

If a Covered Entity believes it is due a refund and has not seen a credit to its wholesaler account by November 17th, it may contact Novo Nordisk Inc., at [NNIBIDNOTIFICATION@novonordisk.com](mailto:NNIBIDNOTIFICATION@novonordisk.com)